Sernova Biotherapeutics (OTCMKTS:SEOVF) (OTCMKTS: SEOVF) is a clinical-stage biotechnology company focused on developing and commercializing innovative cell-based therapies for the treatment of chronic diseases. Headquartered in London, Ontario, Canada, Sernova operates research and development facilities that support the design, engineering and preclinical testing of its proprietary cell delivery technologies. The company’s lead platform, the Cell Pouch®, is an implantable, retrievable device that establishes a prevascularized environment to safely house therapeutic cells, enabling sustained release of essential biological factors.
Building on more than a decade of research, Sernova’s pipeline is anchored by its work in type 1 diabetes, where encapsulated pancreatic islet cells are used to restore endogenous insulin production and improve glycemic control. In parallel, the company is advancing programs in hemophilia, hypothyroidism and other endocrine conditions by leveraging its Cell Pouch technology to deliver cells that secrete clotting factors, hormones or other therapeutic proteins. Sernova maintains collaborative relationships with leading academic and medical institutions in North America and Europe that support its clinical study initiatives.
Since its inception in the late 2000s, Sernova has progressed through multiple stages of clinical and preclinical development, securing regulatory clearances for first-in-human studies and expanding its manufacturing capabilities to meet anticipated demand. The company’s multidisciplinary team includes experts in cell biology, biomaterials, immunology and translational medicine, all working to address key challenges in cell transplantation and immunoprotection.
Under the leadership of President and Chief Executive Officer Dr. Philip Toleikis, Sernova Biotherapeutics is committed to delivering durable and scalable cell therapies that have the potential to transform standard of care for patients with chronic, life-altering conditions. As the company advances its clinical programs toward pivotal trials, it continues to explore strategic partnerships and licensing opportunities aimed at accelerating commercialization and global patient access.
